Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development FRIENDSWOOD, Texas, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized by the Houston Chronicle as a... Read More

Second study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor outcomes FRIENDSWOOD, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the... Read More

FRIENDSWOOD, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 37 th Annual Healthcare Conference on Tuesday, Dec. 2, 2025, at 1:10 p.m. Eastern time. A live audio webcast of the Company’s presentation will be... Read More

Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 36% over Q3 2024 Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million Announced launch of AdvanceAD-Tx™, the Company’s test designed to guide systemic treatment decision making in... Read More

Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared to Th2-targeted therapies FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the launch of AdvanceAD-Tx™, a gene expression profile... Read More

FRIENDSWOOD, Texas, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens 27 th Annual Investment Conference on Wednesday, Nov. 19, 2025, at 10:00 a.m. Eastern time. A live audio webcast of the Company’s presentation will be... Read More

Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for research deemed high quality, novel or unique FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data... Read More

This new histological subtype data confirms DecisionDx-Melanoma’s clinical value across the spectrum of melanoma Castle Biosciences will also present validation data on its atopic dermatitis pipeline test FRIENDSWOOD, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it is presenting data on its... Read More

FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2025, after the close of market on Monday, Nov. 3, 2025. Company management will host a conference call and webcast to discuss its financial... Read More

Maetzold recognized among 586 applicants to The CEO Magazine’s 2025 Executive of the Year Awards — United States program FRIENDSWOOD, Texas, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded the CEO of the Year by The CEO... Read More

FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized as a Greater Pittsburgh Top Workplace by The Pittsburgh Post-Gazette . The designation is based exclusively on anonymous employee feedback gathered through a third-party survey. The confidential survey measures... Read More

FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek. The ranking honors 650 U.S. companies demonstrating strong performance across four key pillars: financial strength, workforce dedication, innovation, and... Read More

In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated with low-grade dysplasia (LGD); current guidelines recommend prompt intervention for LGD to prevent disease progression FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company... Read More

New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms test results align with treatment decision-making thresholds for adjuvant radiation therapy and surveillance imaging FRIENDSWOOD, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company... Read More

FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird’s 2025 Global Healthcare Conference on Wednesday, Sept. 10, 2025, at 10:15 a.m. Eastern time. A live audio webcast of the Company’s presentation will be... Read More

Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health... Read More

FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 45 th Annual Growth Conference on Tuesday, Aug. 12, 2025, at 12:30 p.m. Eastern time. A live audio webcast of the Company’s presentation will... Read More

The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful organizations FRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder,... Read More

FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its DecisionDx-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). DecisionDx-Melanoma is a gene expression profile (GEP) test that provides comprehensive, personalized... Read More

Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces program: a... Read More

FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30... Read More

FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 66 employees covering an aggregate of 135,978 shares of common stock as an inducement material to their entering into... Read More

Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic Dermatitis FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB (“SciBase”) utilizing SciBase’s Electrical Impedance... Read More

FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during the 2025 BIO International Convention (BIO 2025), being held June... Read More

Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been... Read More

Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients FRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal... Read More

FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. A live audio webcast of the Company’s presentation will be... Read More

The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awareness throughout May Castle highlights cancer journey of melanoma survivor and advocate, Leah Adams FRIENDSWOOD, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is... Read More

Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, DecisionDx ® -SCC, TissueCypher ® ) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL),... Read More

Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to... Read More

Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC” FRIENDSWOOD, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new... Read More

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery FRIENDSWOOD, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today... Read More

FRIENDSWOOD, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc . (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders. DecisionDx-Melanoma is a 31-gene expression profile test that provides comprehensive, personalized results designed to improve... Read More

FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous and uveal melanoma (CM and UM, respectively) via poster presentations at the American Association for Cancer Research ® (AACR) Annual Meeting 2025, being held April 25-30 in... Read More

FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30... Read More

FRIENDSWOOD, Texas, April 08, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key educational programs and initiatives throughout the month of April in recognition of Esophageal Cancer Awareness Month. The Company is proudly collaborating with the Esophageal Cancer Action Network (ECAN), the American Foregut Society... Read More

FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top Workplaces USA Award for the fourth consecutive year. The national award program by Energage and USA Today celebrates organizations with 150 or more employees that have built exceptional workplace cultures.... Read More

Consistent with prior studies, published results from Castle’s DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph node biopsy (SLNB) surgical procedure, and who are also unlikely to experience disease progression 1,2 As of the last follow-up, all of the patients in the third study... Read More

Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant therapy, and the role of the test in prompting use of imaging surveillance in early-stage patients at high risk of metastasis to the central nervous system (CNS) FRIENDSWOOD, Texas, April 01, 2025 (GLOBE NEWSWIRE) -- Castle... Read More

New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by National Comprehensive Cancer Network (NCCN) guidelines to support improved, risk-aligned treatment pathway decisions Castle will... Read More

New study corroborates DecisionDx ® -SCC's ability to independently predict metastatic risk in patients with high-risk cutaneous squamous cell carcinoma (SCC) Landmark analysis of nearly 10,000 patients through Castle's collaboration with the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program Registries showed a significant association between DecisionDx ® -Melanoma testing and improved... Read More

Full-year 2024 revenue of $332 million, an increase of 51% compared to 2023 and above previously reported guidance Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities of $293 million, a $50 million increase compared to 2023 Anticipate generating between $280-295 million in total revenue in 2025 Conference call and webcast... Read More

FRIENDSWOOD, Texas / Feb 25, 2025 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the following investor conferences next month: Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40 p.m. Eastern time. KeyBanc Capital Markets... Read More

FRIENDSWOOD, Texas / Feb 12, 2025 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of gene expression profile (GEP) tests at the 2025 Winter Clinical Dermatology Conference - Hawaii, taking place Feb. 14-19 in Waikoloa Village, Hawaii. “As long-standing supporters of the Winter Clinical... Read More

FRIENDSWOOD, Texas / Feb 06, 2025 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2024, after the close of market on Thursday, Feb. 27, 2025. Company management will host a conference call and webcast to discuss its financial results... Read More

Highlights from Castle’s DecisionDx-SCC poster will be shared in a special podium presentation during the Late Breakers 2025 session on Tuesday, Jan. 21, from 10:45-11:15 a.m. local time FRIENDSWOOD, Texas / Jan 17, 2025 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of tests for skin... Read More

2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023 Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities expected to be approximately $293 million FRIENDSWOOD, Texas / Jan 12, 2025 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company... Read More

With this approval, all of the tests in Castle’s dermatology, gastroenterology and ophthalmology portfolios, as well as its clinical laboratories in Phoenix and Pittsburgh, are now approved by the state of New York FRIENDSWOOD, Texas--( BUSINESS WIRE )-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval... Read More

Assuming successful validation, the Company currently expects to launch the pipeline test by the end of 2025 FRIENDSWOOD, Texas / Dec 23, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis (AD) who are... Read More

FRIENDSWOOD, Texas / Dec 19, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 13, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 135 employees covering an aggregate of 173,542 shares of common stock as an inducement material to their entering into... Read More

This recently published meta-analysis encompasses 13 peer-reviewed publications involving thousands of patients and affirms the powerful risk stratification provided by DecisionDx-Melanoma and its potential to significantly improve care for patients with cutaneous melanoma (CM) FRIENDSWOOD, Texas / Dec 12, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that... Read More

FRIENDSWOOD, Texas / Nov 20, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 36 th Annual Healthcare Conference on Wednesday, Dec. 4, 2024, at 10:50 a.m. Eastern time. A live audio webcast of the Company’s presentation will... Read More

Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development FRIENDSWOOD, Texas / Nov 19, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been named a Houston Top Workplace for 2024 by the... Read More

FRIENDSWOOD, Texas / Nov 08, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the American Society of Dermatopathology (ASDP) 61 st Annual Meeting, being held Nov. 7-10, in Chicago. “At Castle, we focus strongly on... Read More

TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal cancer FRIENDSWOOD, Texas / Nov 07, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s TissueCypher Barrett’s... Read More

Study shows a 25% reduction in unnecessary sentinel lymph node biopsy (SLNB) procedures performed when patient’s DecisionDx-Melanoma test results were integrated into clinical decision-making Among patients electing to have an SLNB, no positive nodes were identified among those with low-risk DecisionDx-Melanoma test results (i.e., predicted sentinel lymph node (SLN) positivity risk of less than 5%), supporting use of the... Read More

Q3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas / Nov 04, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today... Read More

TissueCypher abstract awarded a Presidential Poster Award by ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for high quality, novel, unique or interesting research FRIENDSWOOD, Texas / Oct 29, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating a significant... Read More

FRIENDSWOOD, Texas / Oct 28, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the following investor conferences next month: Guggenheim Securities Healthcare Innovation Conference on Nov. 11, 2024, at 2:30 p.m. Eastern time. Stephens 26 th... Read More

Data from prospective, multicenter CONNECTION study indicate that using DecisionDx-Melanoma test results to guide sentinel lymph node biopsy (SLNB) decisions in patients with T1 melanoma tumors could have reduced the number of unnecessary biopsies by up to 64%, which, in turn, could have reduced procedure-related complications and health care costs New findings support DecisionDx ® -SCC’s use in guiding radiologic... Read More

Two studies published in the Journal of Cutaneous Pathology and Melanoma Management demonstrate the significant disagreement that exists in the diagnosis of melanocytic lesions using pathology alone, the variability of surgical management of lesions among treating dermatologists, and the risk-aligned changes and confidence in these decisions that can result from GEP testing 1,2 FRIENDSWOOD, Texas / Oct 16, 2024 / Business... Read More

FRIENDSWOOD, Texas / Oct 14, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2024, after the close of market on Monday, Nov. 4, 2024. Company management will host a conference call and webcast to discuss its financial... Read More

FRIENDSWOOD, Texas / Oct 11, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will sponsor the 71st Annual Montagna Symposium on the Biology of the Skin, hosted by the Oregon Health & Science University (OHSU) Department of Dermatology and being held Oct. 17-21, 2024, in Stevenson, Washington. “Castle is proud... Read More

FRIENDSWOOD, Texas / Oct 09, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will present new data related to its DecisionDx-Melanoma and DecisionDx ® -UM tests for patients with cutaneous melanoma (CM) and uveal melanoma (UM), respectively, at the 21 st International Congress of the Society for Melanoma... Read More

FRIENDSWOOD, Texas / Oct 02, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will hold a groundbreaking ceremony to celebrate the recent construction start of its new corporate campus and office building. The... Read More

In the study, patients with lower-stage Brigham and Women's Hospital (BWH) T1-T2a cutaneous squamous cell carcinoma (SCC) tumors were further stratified into distinct groups of those with more or less favorable survival by the DecisionDx-SCC test, including in the T2a immunosuppressed patient subset which showed a higher rate of metastasis FRIENDSWOOD, Texas / Sep 27, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq:... Read More

Oral abstract will share data showing that TissueCypher alone, compared to combining the test’s results with a patient’s clinicopathologic risk factors, like age and pathology diagnosis, is the strongest predictor of progression to esophageal cancer Poster will highlight ability of the test to guide important patient management decisions, including upstaging care for high-risk patients and supporting long-interval... Read More

PHOENIX & FRIENDSWOOD, Texas / Sep 16, 2024 / Business Wire / The Arizona Bioindustry Association, Inc. (AZBio) and Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Kristen Oelschlager, R.N., Castle’s chief operating officer, has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year. The award, presented by AZBio,... Read More

Using the DecisionDx-Melanoma test to guide sentinel lymph node biopsy (SLNB) surgery decisions could have significantly reduced the number of unnecessary SLNBs by 33% for patients with T1-T2 melanoma tumors FRIENDSWOOD, Texas / Sep 11, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study... Read More

This is the second study to demonstrate the ability of the DecisionDx-SCC test to identify patients who are more or less likely to benefit from adjuvant radiation therapy (ART), confirmed in an independent cohort of high-risk cutaneous squamous cell carcinoma (SCC) patients FRIENDSWOOD, Texas / Sep 05, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that... Read More

FRIENDSWOOD, Texas / Aug 28, 2024 / Business Wire / Castle Biosciences, Inc . (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird’s 2024 Global Healthcare Conference on Wednesday, Sept. 11, 2024, at 9:05 a.m. Eastern time. A live audio webcast of the Company’s presentation will be... Read More

Q2 2024 revenue increased 74% over Q2 2023 to $87 million Q2 2024 total test reports increased 49% over Q2 2023 Raising full-year 2024 revenue guidance to $275-300 million from $255-265 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas / Aug 05, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today... Read More

FRIENDSWOOD, Texas / Jul 30, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at 12:30 p.m. Eastern time. A live audio webcast of the Company’s presentation will be... Read More

Campaign will focus on empowering patients impacted by melanoma FRIENDSWOOD, Texas / Jul 22, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the Two T’s in a Pod podcast and stage II melanoma survivor Teddi Mellencamp Arroyave to... Read More

FRIENDSWOOD, Texas / Jul 15, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Company management will host a conference call and webcast to discuss its financial... Read More

Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards FRIENDSWOOD, Texas / Jul 11, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2024 Top Workplaces program,... Read More

Castle’s TissueCypher test has been shown to improve the risk stratification of patients with Barrett’s esophagus (BE) 1,2 FRIENDSWOOD, Texas / Jun 24, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the latest American Gastroenterological Association (AGA) clinical practice guideline recognized that not all... Read More

FRIENDSWOOD, Texas / Jun 20, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 94 employees covering an aggregate of 158,197 shares of common stock as an inducement material to their entering into... Read More

Maetzold selected as a winner of Ernst & Young’s prestigious annual awards among 48 visionary finalists in the Gulf South region, encompassing Central and South Texas, Louisiana and Mississippi FRIENDSWOOD, Texas / Jun 14, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive... Read More

Castle to present a second poster on its DecisionDx®-UM test sharing data from an ongoing prospective, multi-center study of patients with uveal melanoma (UM) led by the Collaborative Ocular Oncology Group (COOG2) FRIENDSWOOD, Texas / May 30, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will present new... Read More

In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher metastasis-free survival (MFS) rates, on average, and slowed disease progression compared to Class 2B patients who did not receive ART Patients with Class 1 test results, predicted to have a lower risk of metastasis, did not see... Read More

FRIENDSWOOD, Texas / May 15, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 2:00 p.m. Eastern time. A live audio webcast of the Company’s presentation will... Read More

In collaboration with leading GI experts, Castle has also planned several educational sessions at DDW 2024, including a product theater and two American Society for Gastrointestinal Endoscopy (ASGE) theater talks FRIENDSWOOD, Texas / May 14, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share three abstracts supporting the... Read More

This marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutions FRIENDSWOOD, Texas / May 10, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the “Best Overall Mental Health Solution” award in the eighth annual... Read More

Oral presentation at ARVO shares ground-breaking findings from the ongoing Collaborative Ocular Oncology Group (COOG) study 2 (COOG2) of patients with uveal melanoma (UM) FRIENDSWOOD, Texas / May 08, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a study further confirming the performance of its... Read More

FRIENDSWOOD, Texas / May 03, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting the utility of its DecisionDx-SCC test in patients with high-risk cutaneous squamous cell carcinoma (SCC) tumors located on the head and neck (H&N) will be shared at the 56th American College of Mohs Surgery (ACMS)... Read More

Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $255-265 million from $235-240 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas / May 02, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today... Read More

The Company is proud to collaborate on a number of additional initiatives during the month of May FRIENDSWOOD, Texas / Apr 30, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a... Read More

FRIENDSWOOD, Texas / Apr 11, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2024, after the close of market on Thursday, May 2, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30... Read More

FRIENDSWOOD, Texas / Apr 10, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April. The Company is proud to continue its ongoing collaboration with the Esophageal Cancer Action Network... Read More

FRIENDSWOOD, Texas / Apr 10, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that, for the second year in a row, its chief financial officer, Frank Stokes, has been selected as a Top 25 CFO of Houston by TOP CFOs (formerly Finance & Investing). The annual award recognizes the top-performing CFOs by region, selected... Read More

If choosing to use a molecular test to rule-out a sentinel lymph node biopsy (SLNB) in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk outcomes; Castle’s poster on DecisionDx-Melanoma shows that patients foregoing an SLNB due to a DecisionDx-Melanoma test result have low risk outcomes A second poster on DecisionDx-Melanoma shows that using the test’s results to guide... Read More

FRIENDSWOOD, Texas / Apr 02, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 12:45 p.m. Eastern time. A live audio webcast of the Company’s... Read More

FRIENDSWOOD, Texas / Mar 27, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Rodney Cotton has been appointed to its board of directors, effective immediately, and will stand for election at Castle’s 2024 Annual Meeting of Stockholders, expected to be held in May 2024. The Company further announced that Mara G.... Read More

Company honored for creating an exceptional, people-first culture that empowers employees and fosters trust, transparency and authenticity FRIENDSWOOD, Texas / Mar 25, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top Workplaces USA award for the third consecutive year. The national award... Read More

Castle’s second presentation at SSO 2024 shows that in a study of 979 patients, DecisionDx-Melanoma demonstrated clinical use value in patients with TI cutaneous melanoma (CM), identifying high-risk patients who could consider a more intensive treatment pathway, such as a sentinel lymph node biopsy (SLNB) and imaging surveillance FRIENDSWOOD, Texas / Mar 22, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a... Read More

The consensus guidelines were drafted by a multidisciplinary panel of radiation oncologists and dermatologists/Mohs micrographic surgeons with expertise in cutaneous squamous cell carcinoma (SCC) management; they provide a recommended framework for using DecisionDx-SCC testing with American Joint Committee on Cancer 8 th Edition (AJCC8) staging to guide decisions regarding the use of adjuvant radiation therapy (ART) in... Read More

Study data show that one-third of the IDgenetix-guided medication recommendations were due to drug-drug interactions and lifestyle factors, demonstrating the value of this additional information in guiding selection of neuropsychiatric medications for older adults in cohort of patients 65 and older, with majority being on five or more medications at the time of testing FRIENDSWOOD, Texas / Mar 15, 2024 / Business Wire /... Read More

FRIENDSWOOD, Texas / Mar 12, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 11:15 a.m. Eastern time. A live audio webcast of... Read More

Castle’s presentations at AAD include the latest findings from the Company’s ongoing collaboration with the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program Registries, providing new data from a study of more than 5,000 patients confirming that testing with DecisionDx®-Melanoma is associated with improved survival in patients with cutaneous melanoma (CM) FRIENDSWOOD, Texas / Mar 08, 2024... Read More

Largest study of gene expression profile testing in patients with high-risk cutaneous squamous cell carcinoma (SCC) supports test’s ability to provide clinically actionable risk stratification to guide treatment decisions for patients diagnosed with this impactful skin cancer FRIENDSWOOD, Texas / Mar 07, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that... Read More

Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment securities of $243 million Two critical peer-reviewed publications in 2023 demonstrating an association with DecisionDx®-Melanoma testing and improved patient outcomes... Read More

Study results, which include 5,651 patients in the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program Registries, support the use of DecisionDx-Melanoma in stage I melanoma to help inform clinical decision-making FRIENDSWOOD, Texas / Feb 26, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today... Read More

FRIENDSWOOD, Texas / Feb 07, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2023, after the close of market on Wednesday, Feb. 28, 2024. Company management will host a conference call and webcast to discuss its financial results... Read More

Study finds that using DecisionDx-SCC to guide patient selection for adjuvant radiation therapy (ART), identifying patients with cutaneous squamous cell carcinoma (SCC) who can safely forgo the treatment, could result in significant savings to the healthcare system FRIENDSWOOD, Texas / Jan 18, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide... Read More

FRIENDSWOOD, Texas / Jan 14, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data across its dermatologic portfolio of commercially available and pipeline gene expression profile (GEP) tests at the 2024 Winter Clinical Dermatology Conference - Hawaii, being held Jan. 12-17 in Honolulu, Hawaii. “We are committed to... Read More

FRIENDSWOOD, Texas / Jan 09, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its Chief Operating Officer, Kristen Oelschlager, has been named to The Healthcare Technology Report’s Top 25 Women Leaders in Biotechnology of 2023. The honorees “stand as a driving force, ensuring diverse perspectives on scientific... Read More

Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022 Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment securities expected to be approximately $243 million FRIENDSWOOD, Texas / Jan 07, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through... Read More

FRIENDSWOOD, Texas / Dec 20, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 18, 2023, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 52 employees covering an aggregate of 170,913 shares of common stock as an inducement material to their entering into... Read More

In a survey of nurse practitioners and physician assistants (NPs/PAs), 82.4% of respondents who use DecisionDx-Melanoma in clinical practice stated that a high-risk test result in a thin melanoma tumor (≤1mm) would impact their patient treatment plan; similarly, 81.3% of test users would alter treatment plans based on a high-risk test result in Stage 1 tumors FRIENDSWOOD, Texas / Dec 01, 2023 / Business Wire / Castle... Read More

Video abstracts reinforce the clinical validity and utility of the Company’s skin cancer test portfolio, including DecisionDx®-Melanoma, DecisionDx®-SCC and MyPath® Melanoma FRIENDSWOOD, Texas / Nov 14, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression... Read More

Castle also earns national recognition through three Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development FRIENDSWOOD, Texas / Nov 13, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been named a Houston Chronicle Top Workplace for the third... Read More

IDgenetix is a clinically validated pharmacogenomic (PGx) test that incorporates drug-gene interactions, drug-drug interactions and lifestyle factors to guide medication management for patients’ neuropsychiatric conditions, such as depression and anxiety FRIENDSWOOD, Texas / Nov 08, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care,... Read More

FRIENDSWOOD, Texas / Nov 08, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this month: Stephens Annual Investment Conference on Nov. 15, 2023, at 11:00 a.m. Eastern Time. Canaccord Genuity... Read More

Renowned eye cancer expert and study investigator, Amy Schefler, M.D., will share early data from a study to explore the potential for developing a complementary test that would be tailored for individuals presenting with small, suspicious lesions of uncertain malignant potential Data will be presented at the 2023 American Academy of Ophthalmology (AAO) Annual Meeting in San Francisco FRIENDSWOOD, Texas / Nov 03, 2023 /... Read More

Castle’s innovative pipeline initiative to develop a genomic test aimed at guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions is targeted to launch by the end of 2025 FRIENDSWOOD, Texas / Nov 02, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced... Read More

Q3 2023 revenue increased 66% over Q3 2022 to $61 million Q3 2023 total test reports increased 52% over Q3 2022 Raising full year 2023 revenue guidance to at least $200 million from at least $180 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas / Nov 02, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care,... Read More

Two posters highlight ability of the TissueCypher test to identify higher- and lower-risk subsets of patients with Barrett’s esophagus than indicated by their clinicopathologic factors to guide risk-aligned patient care FRIENDSWOOD, Texas / Oct 24, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk... Read More

FRIENDSWOOD, Texas / Oct 19, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2023, after the close of market on Thursday, Nov. 2, 2023. Company management will host a conference call and webcast to discuss its financial... Read More

FRIENDSWOOD, Texas / Oct 18, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share new data across its dermatologic portfolio of gene expression profile (GEP) tests at the 2023 Fall Clinical Dermatology Conference® (FC23), taking place Oct. 19-22, 2023, in Las Vegas. “The breadth of data we are sharing at... Read More

Study shows the DecisionDx-Melanoma test identifies more patients who can safely forego SLNB than using current guidelines alone or a clinicopathologic-only nomogram FRIENDSWOOD, Texas / Oct 05, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new study demonstrating DecisionDx®-Melanoma outperforms a nomogram... Read More

FRIENDSWOOD, Texas / Oct 03, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the ability of its DecisionDx ® -SCC test to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of metastasis who may benefit from adjuvant radiation therapy (ART). The data will be... Read More

Data shared via a poster presentation at the recent American Foregut Society (AFS) Annual Meeting FRIENDSWOOD, Texas / Oct 02, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the significant clinical utility of its TissueCypher® Barrett’s Esophagus test in guiding risk-aligned upstaging of care... Read More

Studies have shown that using Castle’s DecisionDx ® -Melanoma test to help guide the care of patients with melanoma, the deadliest form of skin cancer, improves health outcomes 1-5 Castle’s management team will also ring the New York Stock Exchange closing bell on Sept. 28 as a member of the Texas Capital Texas Equity Index exchange traded fund (ETF) FRIENDSWOOD, Texas / Sep 25, 2023 / Business Wire / Castle Biosciences,... Read More

National award recognizes Castle’s strong culture and employee engagement FRIENDSWOOD, Texas / Sep 19, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned a Top Workplaces National Industry Award, ranking third among 84 Top Workplaces in the healthcare industry. Castle has earned several additional Top... Read More

The study, published in Gastroenterology, shows TissueCypher can increase the detection of Barrett’s esophagus (BE) patients with an initial diagnosis of low-grade dysplasia (LGD) who will progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) FRIENDSWOOD, Texas / Sep 14, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient... Read More

FRIENDSWOOD, Texas / Sep 12, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company has received its Clinical Laboratory Permit from the New York State Department of Health for its laboratory in Pittsburgh. “Castle is committed to serving patients through high-quality molecular tests that inform important... Read More

IDgenetix is a clinically validated pharmacogenomic (PGx) test that incorporates the results of drug-gene interactions with drug-drug interactions and lifestyle factors, such as smoking and use of over-the-counter medicines and dietary supplements, to provide medication recommendations for patients with mental health conditions FRIENDSWOOD, Texas / Sep 09, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a... Read More

The TissueCypher Barrett’s Esophagus test can identify patients at a higher or lower risk of developing esophageal cancer than indicated by pathologic diagnoses and clinical risk factors to guide escalated or de-escalated patient management Data to be highlighted at the 19th ISDE World Congress for Esophageal Diseases FRIENDSWOOD, Texas / Sep 08, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company... Read More

FRIENDSWOOD, Texas / Sep 06, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share a poster detailing new data regarding the Company’s IDgenetix® test at the upcoming Psych Congress 2023 conference, being held in Nashville, Tennessee, Sept. 6-10. IDgenetix is Castle’s advanced pharmacogenomic (PGx) test that combines a patient’s... Read More

FRIENDSWOOD, Texas / Sep 05, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at Baird’s 2023 Global Healthcare Conference on Wednesday, Sept. 13, 2023, at 10:15 a.m.... Read More

In the study, management decisions were simulated to determine the most likely care plan with or without use of the TissueCypher test for guidance Study data shows TissueCypher test results significantly improved the likelihood of appropriate management and the consistency of management decisions FRIENDSWOOD, Texas / Aug 07, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through... Read More

Q2 2023 revenue increased 44% over Q2 2022 to $50 million Q2 2023 total test reports increased 52% over Q2 2022 Raising full year 2023 revenue guidance to at least $180 million from $170-180 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas / Aug 02, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today... Read More

FRIENDSWOOD, Texas / Aug 01, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Canaccord Genuity 43 rd Annual Growth Conference on Wednesday, Aug. 9, 2023, at 12:00 p.m. Eastern time. A live audio webcast of the... Read More

FRIENDSWOOD, Texas / Jul 19, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2023, after the close of market on Wednesday, Aug. 2, 2023. Company management will host a conference call and webcast to discuss its financial... Read More

Castle employees to raise funds and awareness for five partner organizations in support of patients impacted by skin cancer, esophageal cancer, mental health conditions and uveal melanoma FRIENDSWOOD, Texas / Jul 18, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, announced that it will host its second company-wide Castle Cares... Read More

Castle also earns national recognition through five Top Workplaces Culture Excellence Awards — Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values FRIENDSWOOD, Texas / Jul 17, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned a second consecutive Arizona Top... Read More

FRIENDSWOOD, Texas / Jul 07, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data on its gene expression profile (GEP) risk-stratification test for patients with cutaneous squamous cell carcinoma (SCC), DecisionDx®-SCC, and its GEP risk-stratification test for patients with cutaneous melanoma (CM),... Read More

Data shows testing with DecisionDx®-Melanoma provided significant prognostic information regarding survival outcomes FRIENDSWOOD, Texas / Jun 30, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in JCO Precision Oncology 1 in which DecisionDx®-Melanoma provided significant, independent risk... Read More

FRIENDSWOOD, Texas / Jun 20, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 16, 2023, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 68 employees covering an aggregate of 197,498 shares of common stock as an inducement material to their entering into... Read More

Data shared during the 2023 Fall Clinical Dermatology Conference for PAs & NPs ® FRIENDSWOOD, Texas / Jun 12, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the ability of the DecisionDx ® -SCC test to identify cutaneous squamous cell carcinoma (cSCC) tumors at a biologically high risk of... Read More

Treatment algorithm can assist clinicians in tailoring their care for patients with high-risk cutaneous squamous cell carcinoma (cSCC) based on individual patient’s unique tumor biology, while adhering to guideline recommendations FRIENDSWOOD, Texas / Jun 05, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the... Read More

FRIENDSWOOD, Texas / Jun 03, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx ® -Melanoma and DecisionDx ® -UM will be shared during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6. DecisionDx-Melanoma is the Company’s genomic risk-stratification... Read More

In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in remission compared to patients whose medication was not guided by the test FRIENDSWOOD, Texas / May 31, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced real-world study data... Read More

The Company is proud to continue ongoing collaborations with The Sun Bus and The Skin Cancer Foundation, including various activities during the month of May FRIENDSWOOD, Texas / May 30, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Skin Cancer Awareness Month and is proud to continue its ongoing... Read More

New data demonstrate the risk-stratification performance and potential of the TissueCypher® Barrett’s Esophagus test to guide risk-aligned patient care decisions FRIENDSWOOD, Texas / May 26, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its three posters at the recent DDW Annual Meeting were honored as “Posters... Read More

The Company expects to double its current workforce in Pittsburgh by the end of 2023 FRIENDSWOOD, Texas / May 22, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has opened a new state-of-the-art laboratory facility in Pittsburgh. “Castle is proud to be a member of the Pittsburgh community and grow our... Read More

This marks the third consecutive year that Castle has been recognized with a MedTech Breakthrough Award for its innovative testing solutions FRIENDSWOOD, Texas / May 15, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare”... Read More

Q1 2023 revenue increased 57% over Q1 2022 to $42 million Q1 2023 total test reports increased 73% over Q1 2022 Reaffirming full-year 2023 revenue is expected to be between $170-180 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas / May 03, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced... Read More

New independent, multi-center study found that patients who received high-risk DecisionDx-Melanoma test results received routine imaging, which led to earlier detection of recurrences, when the tumor burden was lower, which could result in better clinical outcomes FRIENDSWOOD, Texas / May 03, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient... Read More

Thirteen sunscreen dispensers, positioned at rest and lunch stops, will supply sunscreen to the more than 5,200 riders to protect their skin from sunburn during the two-day event FRIENDSWOOD, Texas / Apr 28, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has teamed up with IMPACT Melanoma, one of the nation's... Read More

New data shared in a poster presentation during the 19th European Association of Dermato-Oncology (EADO) Congress FRIENDSWOOD, Texas / Apr 25, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing DecisionDx ® -Melanoma can improve risk stratification over American Joint Committee on Cancer (AJCC) staging... Read More

Data from patient simulation study to be presented at ESGE (European Society of Gastrointestinal Endoscopy) Days 2023 FRIENDSWOOD, Texas / Apr 20, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a patient simulation study which showed that, compared to pathology alone, TissueCypher® Barrett’s Esophagus... Read More

FRIENDSWOOD, Texas / Apr 19, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2023, after the close of market on Wednesday, May 3, 2023. Company management will host a conference call and webcast to discuss its financial results at 4:30... Read More

FRIENDSWOOD, Texas / Apr 12, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023, at 4:30... Read More

FRIENDSWOOD, Texas / Mar 18, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today shared new performance data from a novel, multi-center, independent cohort demonstrating how the independent risk-stratification of DecisionDx®-SCC (the Company’s 40-gene expression profile (GEP) test) can significantly improve metastatic risk... Read More

FRIENDSWOOD, Texas / Mar 14, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Wednesday,... Read More

FRIENDSWOOD, Texas / Mar 10, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting its portfolio of skin cancer gene expression profile (GEP) tests will be showcased in one late-breaking oral presentation and three ePosters at the 2023 American Academy of Dermatology (AAD) Annual Meeting, being held... Read More

FRIENDSWOOD, Texas / Mar 08, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a consensus panel report from the National Society for Cutaneous Medicine recommending use of gene expression profile (GEP) testing in the clinical assessment and management of cutaneous melanoma (CM). The report provides... Read More

FRIENDSWOOD, Texas / Feb 28, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and twelve months ended Dec. 31, 2022. “In 2022, we delivered strong year-over-year growth in revenue and test report volume, reflecting solid execution by our Castle team,” said Derek Maetzold,... Read More

FRIENDSWOOD, Texas / Feb 24, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its chief financial officer, Frank Stokes, was named to Finance & Investing’s Top 25 CFOs of Houston list for 2023. This year’s awardees are financial executives at the forefront of the rapid technological development occurring... Read More

FRIENDSWOOD, Texas / Feb 22, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx ® -Melanoma and the Company’s pipeline test for inflammatory skin diseases was presented at the recent 2023 Winter Clinical - Miami™ conference. The poster presentation for DecisionDx ® -Melanoma strengthens the... Read More

FRIENDSWOOD, Texas / Feb 09, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of data from a prospective, multicenter study, called DECIDE. 1,2 In the study, DecisionDx®-Melanoma test results influenced 85% of clinicians’ decisions regarding the sentinel lymph node biopsy (SLNB) surgical procedure.... Read More

FRIENDSWOOD, Texas / Feb 07, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023. Company management will host a conference call and webcast to discuss its financial results... Read More

Award recognizes Castle’s people-first culture built on the Company’s values of excitement, collaboration, integrity, innovation, trust and excellence FRIENDSWOOD, Texas / Feb 01, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a 2023 Top Workplaces USA award from Energage. This is the second year... Read More

FRIENDSWOOD, Texas / Jan 23, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s medical director, Matthew Goldberg, M.D., F.A.A.D., board-certified dermatologist and dermatopathologist, will present at the Precision Medicine World Conference (PMWC®) 2023, being held Jan. 25-27 in Santa Clara,... Read More

Real-world data from Castle’s collaboration with the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) program registries confirm ability of DecisionDx®-Melanoma to identify patients with high-risk tumor biology in a cohort of patients with a negative lymph node New clinician-developed real-world algorithm provides a framework to incorporate DecisionDx®-SCC test results into clinical practice... Read More

2022 total revenue expected to meet or exceed top end of guided range of $132–137 million Delivered 44,338 total test reports in 2022, an increase of 58% compared to 2021 Growth of 37% year over year in DecisionDx ® -Melanoma test report volume Year-end 2022 cash, cash equivalents and marketable investment securities expected to be approximately $259 million Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health... Read More